Planning with Dm,m as with Dw,w can be
disruptive.
There are systematic differences in dose
prescription and constraints. For water-like tissues, 1% water/muscle
difference is addressed in AAPM TG329. For bony tissues, either specific Dm,m
constraints should be used, or the different Dm,m response should be switched
off by recalculating in Dw,w or, more accurately, dose to reference-like medium
(Dref,m*).
Forcing homogeneous Dm,m distributions can
introduce local fluence increases, deviating from previous practice. They
increase NTCP if found in an OAR and impair robustness if their position
mismatches the heterogeneity. Improving robustness implies using more
homogeneous fluences while sacrificing PTV Dm,m homogeneity. Hence, Dm,m robust
optimisation should be implemented.
Homogeneous photon fluences resemble
previous practice but can result in inhomogeneous Dm,m distributions difficult
to evaluate. ICRU criteria should be adapted for target homogeneity, minimum,
etc Alternatively, distributions can be recalculated in terms of Dw,w or
Dref,m*.
These issues should be considered in guidelines
for Dm,m planning and evaluation, especially when consistency is critical, as
in clinical trials and planning automation.